Prediction of conversion to wet age-related macular degeneration (AMD)

Prevalence of subclinical Non-Exudative choroidal neovascularisation and its contribution to prediction of exudatiON in fellow eyes with unilateral exudative AMD (EYE-NEON)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13798759

Enrollment

800

Registered

2021-07-20

Start date

2021-04-20

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration Eye Diseases

Interventions

This is a non-interventional cohort study and divided into a retrospective and prospective part. The retrospective part will collect retinal images that have been taken as part of routine clinical ca

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive patients at each site who meet the following inclusion and exclusion criteria: 1. Adults who are >=50 years and <=100 years 2. Fellow eyes of patients with unilateral treatment naïve neovascular AMD at baseline 3. Media clarity, pupillary dilation and patient cooperation for adequate imaging 4. Ability to give informed consent Inclusion criteria for retrospective part only in addition to above: 1. Fellow eyes of patients with unilateral neovascular AMD initiated on treatment in the past 12-15 months 2. Had OCT and OCTA for study eye at baseline

Exclusion criteria

Exclusion criteria: 1. Treatment initiation for unilateral neovascular AMD more than 15 months prior to recruitment. 2. Late wet AMD in the study eye 3. Co-existent ocular disease: Any other ocular condition that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study 4. Any patient who has opted out of their information being used for research nationally or locally at any site 5. Patients participating in a clinical trial with an ophthalmic experimental therapy will be excluded 6. Study eye (neCNV) is not treated with anti-VEGF within 6 months for non-wAMD reason

Design outcomes

Primary

Measure	Time frame
1. Age, gender, ethnicity, smoking history, and date of anti-Vascular Endothelial Growth Factor injection of non-study eye measured using patient records at baseline 2. Visual acuity of study eye using ETDRS logs measured at baseline, month 12 and 24 3. Scans of the study eye using Optical Coherence Tomography measured at baseline, month 12 and 24 4. neCNV eyes converted to wAMD measured using Blue Auto Fluorescence and Optical Coherence Tomography Angiography measured at baseline, month 12 and 24	—

Measure

Time frame

1. Age, gender, ethnicity, smoking history, and date of anti-Vascular Endothelial Growth Factor injection of non-study eye measured using patient records at baseline 2. Visual acuity of study eye using ETDRS logs measured at baseline, month 12 and 24 3. Scans of the study eye using Optical Coherence Tomography measured at baseline, month 12 and 24 4. neCNV eyes converted to wAMD measured using Blue Auto Fluorescence and Optical Coherence Tomography Angiography measured at baseline, month 12 and 24

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, Northern Ireland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 23, 2026